Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MVRBF's Cash to Debt is ranked higher than
88% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. MVRBF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MVRBF' s Cash to Debt Range Over the Past 10 Years
Min: 10.06  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
MVRBF's Equity to Asset is ranked higher than
84% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MVRBF: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
MVRBF' s Equity to Asset Range Over the Past 10 Years
Min: 0.75  Med: 0.86 Max: 0.92
Current: 0.9
0.75
0.92
F-Score: 5
Z-Score: 6.32
WACC vs ROIC
9.65%
-4.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.45
MVRBF's Operating margin (%) is ranked higher than
70% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. MVRBF: -0.45 )
Ranked among companies with meaningful Operating margin (%) only.
MVRBF' s Operating margin (%) Range Over the Past 10 Years
Min: -393.87  Med: -14.72 Max: 67.27
Current: -0.45
-393.87
67.27
Net-margin (%) -6.21
MVRBF's Net-margin (%) is ranked higher than
66% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. MVRBF: -6.21 )
Ranked among companies with meaningful Net-margin (%) only.
MVRBF' s Net-margin (%) Range Over the Past 10 Years
Min: -381.36  Med: -25.52 Max: 64.11
Current: -6.21
-381.36
64.11
ROE (%) -2.20
MVRBF's ROE (%) is ranked higher than
73% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. MVRBF: -2.20 )
Ranked among companies with meaningful ROE (%) only.
MVRBF' s ROE (%) Range Over the Past 10 Years
Min: -69.41  Med: -6.41 Max: 79.91
Current: -2.2
-69.41
79.91
ROA (%) -1.93
MVRBF's ROA (%) is ranked higher than
74% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. MVRBF: -1.93 )
Ranked among companies with meaningful ROA (%) only.
MVRBF' s ROA (%) Range Over the Past 10 Years
Min: -52.66  Med: -12.94 Max: 71.26
Current: -1.93
-52.66
71.26
ROC (Joel Greenblatt) (%) -42.22
MVRBF's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. MVRBF: -42.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MVRBF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -518.6  Med: -22.00 Max: 1010.26
Current: -42.22
-518.6
1010.26
Revenue Growth (3Y)(%) 8.40
MVRBF's Revenue Growth (3Y)(%) is ranked higher than
59% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MVRBF: 8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MVRBF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: -3.60 Max: 118.5
Current: 8.4
-46.4
118.5
» MVRBF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MVRBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XPAR:COX, TSE:4585, XKRX:141080, OTCPK:CTIX, NAS:BCRX, ROCO:3205 » details
Traded in other countries:MVR.Germany, MVIR B.Sweden, 0GP7.UK,
Medivir AB is a research based pharmaceutical company with a focus on infectious diseases and oncology. It is engaged in the design of protease inhibitors and in the science of nucleotides and nucleosides.

Medivir AB is a pharmaceutical company with an R&D focus on infectious diseases and hepatitis C. The Company works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Its research focuses on infectious diseases and has expertise in the chemistry and biology of the enzyme classes, polymerase and protease. The research portfolio comprises nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by the Company and Janssen. Positive simeprevir phase III data was reported in December 2012 that will, together with previous phase II data, form the basis for registration applications in the USA, Europe and Japan. The Company markets pharmaceuticals in the Nordic market. The product range comprises approximately 16 prescription pharmaceuticals in different therapeutic spheres. The products include Citodon, Laxabon,Lithionit, Mollipect and Paraflex. Parallel imports of pharmaceuticals to the Swedish market are conducted via the wholly owned subsidiary company, Cross Pharma.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 30.69
MVRBF's Price/Owner Earnings (ttm) is ranked higher than
55% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 34.28 vs. MVRBF: 30.69 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MVRBF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.19  Med: 5.68 Max: 59.09
Current: 30.69
2.19
59.09
P/B 0.95
MVRBF's P/B is ranked higher than
93% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. MVRBF: 0.95 )
Ranked among companies with meaningful P/B only.
MVRBF' s P/B Range Over the Past 10 Years
Min: 0.91  Med: 2.21 Max: 14.04
Current: 0.95
0.91
14.04
P/S 2.77
MVRBF's P/S is ranked higher than
83% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. MVRBF: 2.77 )
Ranked among companies with meaningful P/S only.
MVRBF' s P/S Range Over the Past 10 Years
Min: 1.33  Med: 5.86 Max: 83.31
Current: 2.77
1.33
83.31
PFCF 32.32
MVRBF's PFCF is ranked lower than
53% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 28.09 vs. MVRBF: 32.32 )
Ranked among companies with meaningful PFCF only.
MVRBF' s PFCF Range Over the Past 10 Years
Min: 1.82  Med: 30.96 Max: 34625
Current: 32.32
1.82
34625
POCF 23.05
MVRBF's POCF is ranked higher than
50% of the 192 Companies
in the Global Biotechnology industry.

( Industry Median: 23.05 vs. MVRBF: 23.05 )
Ranked among companies with meaningful POCF only.
MVRBF' s POCF Range Over the Past 10 Years
Min: 1.79  Med: 26.91 Max: 2004.55
Current: 23.05
1.79
2004.55
Current Ratio 7.51
MVRBF's Current Ratio is ranked higher than
68% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. MVRBF: 7.51 )
Ranked among companies with meaningful Current Ratio only.
MVRBF' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.37 Max: 11.67
Current: 7.51
1.84
11.67
Quick Ratio 7.35
MVRBF's Quick Ratio is ranked higher than
68% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MVRBF: 7.35 )
Ranked among companies with meaningful Quick Ratio only.
MVRBF' s Quick Ratio Range Over the Past 10 Years
Min: 1.83  Med: 4.36 Max: 11.49
Current: 7.35
1.83
11.49
Days Inventory 85.03
MVRBF's Days Inventory is ranked higher than
65% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. MVRBF: 85.03 )
Ranked among companies with meaningful Days Inventory only.
MVRBF' s Days Inventory Range Over the Past 10 Years
Min: 49.91  Med: 71.88 Max: 283.02
Current: 85.03
49.91
283.02
Days Sales Outstanding 16.87
MVRBF's Days Sales Outstanding is ranked higher than
84% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. MVRBF: 16.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
MVRBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.35  Med: 17.57 Max: 93.15
Current: 16.87
6.35
93.15
Days Payable 140.03
MVRBF's Days Payable is ranked higher than
76% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. MVRBF: 140.03 )
Ranked among companies with meaningful Days Payable only.
MVRBF' s Days Payable Range Over the Past 10 Years
Min: 34.12  Med: 104.62 Max: 8532.47
Current: 140.03
34.12
8532.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.51
MVRBF's Price/Net Cash is ranked higher than
92% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. MVRBF: 1.51 )
Ranked among companies with meaningful Price/Net Cash only.
MVRBF' s Price/Net Cash Range Over the Past 10 Years
Min: 1.71  Med: 10.18 Max: 34.18
Current: 1.51
1.71
34.18
Price/Net Current Asset Value 1.35
MVRBF's Price/Net Current Asset Value is ranked higher than
93% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 5.18 vs. MVRBF: 1.35 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MVRBF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.53  Med: 5.67 Max: 15.7
Current: 1.35
1.53
15.7
Price/Tangible Book 1.32
MVRBF's Price/Tangible Book is ranked higher than
90% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MVRBF: 1.32 )
Ranked among companies with meaningful Price/Tangible Book only.
MVRBF' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.49  Med: 4.30 Max: 10.89
Current: 1.32
1.49
10.89
Price/Projected FCF 0.36
MVRBF's Price/Projected FCF is ranked higher than
98% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. MVRBF: 0.36 )
Ranked among companies with meaningful Price/Projected FCF only.
MVRBF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.4  Med: 1.66 Max: 34.35
Current: 0.36
0.4
34.35
Price/Median PS Value 0.47
MVRBF's Price/Median PS Value is ranked higher than
84% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. MVRBF: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
MVRBF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.01 Max: 13.87
Current: 0.47
0.23
13.87
Earnings Yield (Greenblatt) (%) -4.60
MVRBF's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. MVRBF: -4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MVRBF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.6  Med: 12.40 Max: 96.7
Current: -4.6
-4.6
96.7

More Statistics

Revenue (TTM) (Mil) $62.03
EPS (TTM) $ -0.14
Beta0.55
Short Percentage of Float0.00%
52-Week Range $7.52 - 10.63
Shares Outstanding (Mil)26.84

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)